B7H3 ADC

B7H3 ADC refers to a class of antibody-drug conjugates (ADCs) designed to target the CD276 antigen, commonly known as B7-H3. B7-H3 is a transmembrane protein and a member of the B7 family of immune-modulatory proteins, which is significantly overexpressed in a wide range of solid tumors—including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and prostate cancer—while exhibiting minimal expression in normal tissues. This differential expression makes it an attractive target for ADC-based therapies. These agents typically comprise a humanized anti-B7-H3 monoclonal antibody conjugated to a potent cytotoxic payload, such as a topoisomerase I inhibitor or a DNA-alkylating agent, via a stable or cleavable linker. Upon binding to the tumor cell surface, the ADC is internalized through endocytosis, and the payload is released to induce cell death. Several B7-H3 ADCs are currently in clinical development, most notably ifinatamab deruxtecan (DS-7300), vobramitamab duocarmazine (MGC018/GSK4527226), and GSK5764227 (HS-20093).

Other names

B7-H3 ADCB-7-H3 ADCB 7-H3 ADCCD276 ADCCD-276 ADCCD 276 ADCB7-H3-targeted antibody-drug conjugateB-7-H3-targeted antibody-drug conjugateB 7-H3-targeted antibody-drug conjugate